The estimated Net Worth of Pad Chivukula is at least $21.2 Million dollars as of 5 June 2024. Dr Chivukula owns over 114 units of Arcturus Therapeutics Inc stock worth over $9,385,067 and over the last 6 years he sold ARCT stock worth over $11,154,374. In addition, he makes $640,000 as Founder, Chief Scientific Officer, and COO & Sec. at Arcturus Therapeutics Inc.
Sign up
Dr Chivukula ARCT stock SEC Form 4 insiders trading
Dr has made over 29 trades of the Arcturus Therapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 114 units of ARCT stock worth $5,130 on 5 June 2024.
The largest trade he's ever made was selling 26,000 units of Arcturus Therapeutics Inc stock on 3 June 2024 worth over $1,040,260. On average, Dr trades about 7,863 units every 39 days since 2019. As of 5 June 2024 he still owns at least 447,334 units of Arcturus Therapeutics Inc stock.
You can see the complete history of Dr Chivukula stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. Padmanabh Chivukula biography
Dr. Padmanabh Chivukula is the Founder, Chief Scientific Officer, COO & Sec. at Arcturus Therapeutics Inc.
What is the salary of Dr Chivukula?
As the Founder, Chief Scientific Officer, and COO & Sec. of Arcturus Therapeutics Inc, the total compensation of Dr Chivukula at Arcturus Therapeutics Inc is $640,000. There are 4 executives at Arcturus Therapeutics Inc getting paid more, with Andrew Sassine having the highest compensation of $1,326,880.
How old is Dr Chivukula?
Dr Chivukula is 42, he's been the Founder, Chief Scientific Officer, and COO & Sec. of Arcturus Therapeutics Inc since . There are 10 older and 1 younger executives at Arcturus Therapeutics Inc. The oldest executive at Arcturus Therapeutics Holdings Inc is Edward Holmes, 79, who is the Independent Director.
What's Dr Chivukula's mailing address?
Pad's mailing address filed with the SEC is C/O ARCTURUS THERAPEUTICS HOLDINGS INC., 10628 SCIENCE CENTER DRIVE, SUITE 250, SAN DIEGO, CA, 92121.
Insiders trading at Arcturus Therapeutics Inc
Over the last 12 years, insiders at Arcturus Therapeutics Inc have traded over $137,035,874 worth of Arcturus Therapeutics Inc stock and bought 56,234 units worth $767,374 . The most active insiders traders include William M Kahane, Nicholas S Schorsch, and Peter C Farrell. On average, Arcturus Therapeutics Inc executives and independent directors trade stock every 33 days with the average trade being worth of $1,034,818. The most recent stock trade was executed by Jing L. Marantz on 14 June 2024, trading 3,131 units of ARCT stock currently worth $65,688.
What does Arcturus Therapeutics Inc do?
founded in 2013 and based in san diego, calif., arcturus therapeutics is poised to become an industry leader in the application of rnai technologies for the treatment of disease and improved quality of life. the company’s aim is to develop breakthrough technology and novel therapeutics for rare diseases for which there is no adequate treatment. backed by a management team with extensive experience in the discovery and development of therapeutic modalities, arcturus is on the forefront of research and development of nanoparticle sirna drug delivery systems.
What does Arcturus Therapeutics Inc's logo look like?
Complete history of Dr Chivukula stock trades at Arcturus Therapeutics Inc
Arcturus Therapeutics Inc executives and stock owners
Arcturus Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Andrew Sassine,
Chief Financial Officer, Director -
Joseph Payne,
President, Chief Executive Officer, Director -
Joseph E. Payne M.Sc.,
Founder, Pres, CEO & Director -
Dr. Steven George Hughes M.B.A., M.D.,
Chief Medical Officer -
Dr. Padmanabh Chivukula,
Founder, Chief Scientific Officer, COO & Sec. -
Andrew H. Sassine,
CFO & Director -
Padmanabh Chivukula,
Chief Operating Officer, Chief Scientific Officer -
Lance Kurata,
Chief Legal Officer -
Karah Parschauer,
Director -
Edward Holmes,
Independent Director -
Peter Farrell,
Independent Chairman of the Board -
Magda Marquet,
Independent Director -
James Barlow,
Independent Director -
Steven Hughes,
Chief Development Officer -
Dr. Nirdosh Jagota Ph.D.,
Exec. VP & Chief Regulatory Officer -
Kevin T. Skol,
Sr. VP of Bus. Devel. & Alliance Management -
Neda Safarzadeh,
Sr. Director and Head of Investor Relations/PR & Marketing -
Dr. Dushyant B. Varshney Ph.D.,
Exec. VP & Chief Technology Officer -
Keith C. Kummerfeld CPA,
VP of Fin. & Corp. Controller -
Capital Group, Lpluxor Capi...,
-
William G Stanley,
Director -
Leslie D Michelson,
Director -
Susan E Manning,
See Remarks -
William M Kahane,
President and CEO -
Brian D Jones,
CFO and Treasurer -
Nicholas S Schorsch,
Director -
Robert Burns,
Director -
Pad Chivukula,
Chief Scientific Officer & COO -
Keith C Kummerfeld,
See Remarks -
Andy Sassine,
Chief Financial Officer -
Lance Kurata,
Chief Legal Officer -
Pharmaceutical Inc. Ultragenyx,
Director -
Jing L. Marantz,
Director -
John Markels,
Director -
Moncef Slaoui,
Director